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A B S T R A C T
Foramen ovale plays a very important role in fetal circulation by bypassing the lungs 
and diverting circulation from the right to the left heart. With birth it is usually sealed; 
however, probe patent or incompletely sealed foramen ovale remains in approximately 
25% of adults. Patent foramen ovale (PFO) acquires significance in various congeni-
tal heart diseases or other particular settings leading to a right to left shunt, and thus 
to paradoxical embolism. PFO has been associated with transient ischemic attacks or 
cryptogenic strokes and also a host of other problems, including migraine. The rec-
ognition of an association between migraine syndrome with aura and PFO appears 
to have come ‘full circle’ over the past two decades. Epidemiologic studies have sug-
gested a notably increased PFO prevalence in persons suffering from migraine. The 
prevalence of migraine headache is higher in cryptogenic stroke patients with PFO 
than in the general population. Studies have suggested that closure of the PFO may re-
duce migrainous symptoms. The relation between this association and the recognition 
of migraine as a risk factor for ischemic stroke in the young is unclear, though right 
to left passage of circulating factors has been postulated in both syndromes. Despite 
case series and uncontrolled studies documenting beneficial effects of PFO closure 
in patients with migraine, particularly those also afflicted by cryptogenic stroke, the 
recommendation for PFO closure in patients with migraine alone will need to await 
the results of ongoing randomized trials.
I N T R O D U C T I O N
Migraine is classically defined as an episodic disturbance that manifests prima-
rily as headache of various intensity and sensitivity to afferent stimuli, such as light 
(photophobia), sound (pnonophobia) and head movement [1]. Migraine headaches are 
described as a particular kind of headache characterized by a ‘throbbing’ or ‘pounding’ 
like pain. They are classically located on only one side of the head, but many people 
have migraines with pain on both sides of the head or ‘all- over’. The pain of a migraine 
headache may last for hours or even days. Migraine affects approximately 12% of the 
population, 18% of women and 6% of men [2]. Migraines can be classified into two 
types: with aura and without aura. An aura is a neurological warning symptom that 
precedes the headache. Some patients with migraine headaches experience an ‘aura’ 
10-30 minutes before the onset of the headache. Typical auras may be visual, seeing 
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flashing lights, motor speed difficulty, weakness of an arm or 
leg, or sensory, tingling of the face or hands. Migraine head-
ache with aura is a risk factor for the development of stroke. 
Many patients suffer from frequent and disabling episodes 
[3]. Patients with migraine are at increased risk for subclinical 
lesions in certain brain areas; magnetic resonance imaging 
(MRI) discloses silent infarct areas in the brain that are not 
depicted by computed tomography.
Migraine is co-morbid with numerous other illnesses, 
including psychiatric disorders such as depression, anxiety 
and bipolar disorder, epilepsy and stroke [4]. Strong patho-
physiological links have been identified between migraine 
and these conditions. Various classes of drugs, most of them 
originally designed to fight epilepsy, high blood pressure, or 
some other disorder are used to treat people who have mi-
graines. Daily preventive medications are available for people 
with frequent, debilitating headaches such as antidepressants, 
beta-blockers, calcium channel blockers, medicines also used 
to treat epilepsy and alternative treatments, vitamin B2 and 
magnesium. Yet neurologists’ expectations of success in quell-
ing the headaches are generally modest. Consider topiramate, 
one drug now advertised as a migraine therapy [5]. It reduces 
the frequency of attacks by an average of about 40%, but it 
can cause forgetfulness, fatigue, nausea and skin sensations 
that have no apparent cause. That sort of trade off is typical 
of many migraine drugs [5].
I N T E R A T R I A L  S H U N T S
Historically, migraine has also been associated with heart 
disease, but this has proved difficult to confirm [4]. The re-
lationship between migraine and cardiac right-to-left shunts 
is at best cloudy. Recent evidence has linked migraine to a 
common and usually benign defect of the heart, the patent 
foramen ovale (PFO). Interatrial shunts, particularly PFO and 
atrial septal defect (ASD), are present in about one quarter 
of patients. These shunts have been implicated in cryptogenic 
stroke and decompression illness as a result of paradoxical 
embolism.
Patent foramen ovale first described in 1564 by Leonadi 
Botali, and in 1877 Cohnheim described paradoxical embo-
lism due to PFO. To understand PFO, we should have basic 
knowledge about developmental anatomy and physiological 
changes in circulation taking place after birth. A patent fora-
men ovale is a frequent remnant of embryological development 
with clinical importance in thromboembolism, paradoxical 
embolism, stroke, platypnea-orthodeoxia, decompression 
sickness and migraine headache [6,7]. At birth or shortly 
afterwards, the septum primum and the septum secundum 
usually fuse, closing the interatrial septum to the flow of 
blood. Ostium primum atrial septal defects occur when the 
septum primum fails to fuse with the endocardial cushion. 
Ostium secundum atrial septal defects occur when there is 
excess resorption of septum primum or inadequate develop-
ment of septum secundum. A PFO persists when fusion of 
the septum primum with the septum secundum is inadequate 
[8]. We should remember that PFO is a result of the normal 
developmental process while ASD is the deficiency in the 
formation of atrial septum.
A PFO may allow right to left shunting under conditions of 
transient or permanent increase of right atrial pressure, such 
as during a Valsalva maneuver, coughing, sneezing, diving, 
or elevated heart pressures due to pulmonary hypertension 
or right heart failure. This may lead to conditions favoring 
paradoxical thromboembolism or shunting of chemical sub-
stances (such as serotonin) produced in the liver and ordinarily 
inactivated with their first pass through the lungs but now 
bypassing the pulmonary circulation through the interatrial 
shunt, all these mechanisms also proposed to partly explain 
the occurrence of migraine.
An atrial septal aneurysm (ASA), defined by echocardiog-
raphy as a bulging in the region of the fossa ovalis, is associated 
with a PFO [7,9]. Septum membrane mobility is determined by 
the sum of excursions at rest, essentially the greatest leftward 
and rightward deflections of the septum primum with respect 
to a perpendicular line to the fossa ovalis plane into either the 
left or right atrium. The amount of septal excursion to meet 
this definition is arbitrary, although a sum of 15 mm or more 
has been suggested [10]. The presence of an ASA increases 
the risk of a PFO and more importantly that of a cryptogenic 
stroke or paradoxic embolism; if the association of a PFO 
with cryptogenic strokes has an odds ratio of 5, this odds 
ratio for co-existing ASA climbs to 24. In addition to an ASA, 
other important risk factors for stroke or paradoxic embolism 
include the presence of other predisposing conditions, such 
as the presence of a Eustachian valve or Chiari’s network in 
the right atrium, or underlying venous thrombosis, high right 
atrial pressure, or thrombophilia [11].
D I A G N O S I S  O F  I N T E R A T R I A L  
C O M M U N I C A T I O N
Most people with PFOs have no symptoms or signs of 
the defect. Blood traveling between the atrial chambers of 
the heart may cause symptoms such as fatigue, shortness of 
breath, atrial fibrillation, or other arrhythmias. Patients with 
large PFOs may have a heart murmur, either undetected or 
never evaluated. These may be referred to as benign, where 
in fact they were not. Unfortunately, PFOs and ASDs cannot 
be detected by physical exam only. Transesophageal echocar-
diography (TEE) is the preferred imaging study to confirm a 
PFO because it shows the most detail. We can see the gap in 
mid inter atrial septum or evidence of septal aneurysm with 
septal perforation. Contrast/ bubble echo is very helpful in 
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the diagnosis provided by appearance of micro bubbles in the 
left atrium within three cardiac cycles of their appearance in 
the right atrium which confirms the presence of a PFO. This 
can be made simpler by Valsalva maneuver during contrast 
echo. Also, contrast transcranial Doppler (c-TCD) is a very 
sensitive method to detect right to left shunts, the majority of 
which are due to PFO [12]. This method involves the use of an 
intravenous infusion of air and saline (agitated saline) or other 
contrast medium that produces a suspension of air bubbles 
or contrast particles with a diameter smaller than that of red 
blood cells, but unable to pass through the lung filter. This 
medium when injected into a forearm vein travels to the heart 
and, in case of a right-to-left shunt, it can be detected by tran-
scranial sonography in the arterial tree at the level of middle 
cerebral artery, suggesting possibly a PFO, or other shunts 
[12]. The Valsalva maneuver enhances the sensitivity of the 
test. Recent studies comparing the transcranial sonography 
with the transesophageal Doppler indicate that the Valsalva 
maneuver shows an almost 100% sensitivity in transcranial 
sonography versus transesophageal and a specificity around 
73% [12,13].
P F O  T R E A T M E N T
There is no consensus to treat asymptomatic PFO, but high 
risk PFO should be treated with antiplatelet and anticoagu-
lant drugs. In the case of cryptogenic stroke and failed drug 
therapy, a percutaneous device closure is considered. A PFO 
can be closed without the need for surgery, using a small um-
brella-like device and a percutaneous technique. The closure 
device is advanced into the left atrium through the PFO via 
a long sheath introduced via the femoral vein. This closure 
method is quite safe and effective. The procedure is performed 
with use of local anesthesia and usually takes about 30 minutes 
to complete. Patients typically go home the next day and are 
back to all their usual activities in a few days. Complications of 
the procedure may include thromboembolism, local bleeding, 
infection, device embolization, cardiac perforation and need 
for urgent surgery [14]. The closure devices are not affected 
by magnetic resonance imaging (MRI) or metal detectors as 
they are not metallic in nature.
R E L A T I O N  O F  P F O  A N D  M I G R A I N E
Recent studies have tied the occurrence of migraine to 
the presence of a PFO. A family history is present in up to 
90% of patients with migraine [15]. Usually there is dominant 
inheritance with incomplete penetrance [15]. The incidence 
of interatrial communications, primarily PFOs, appears to 
be increased in patients with migraine, especially in patients 
who experience migraine with aura [16]. There is a 3.5-fold 
increased incidence of migraine headache in patients with a 
PFO or atrial septal defect (ASD) who are undergoing trans-
catheter closure of their interatrial communication. Trans-
catheter closure of PFO or ASD in patients with migraine 
leads to resolution of or significant improvement in severity 
of migraine in the majority of patients [16].
How could a PFO trigger migraine? It is thought that cer-
tain vasoactive substances in the body, like serotonin, that are 
normally taken up by the lungs, could pass unfiltered via a 
PFO to the blood destined for the brain, triggering a migraine 
in susceptible individuals. Why might this be? It is possible 
that blood without enough oxygen may trigger a migraine 
when it reaches the brain. The pain of migraine headache is 
thought to be caused by abnormal dilation of the brain blood 
vessels. The aura that precedes the headache in many people 
is thought to represent abnormal constriction of the blood 
vessels before they dilate. This constriction leads to a low 
blood flow in that area of the brain, and transient ischemia 
which causes the symptoms of aura. There are several fac-
tors that may trigger this hyperactivity of the blood vessels. 
Certain foods especially those containing substances that are 
‘vasoactive’ like red wine, chocolate and aged cheese are often 
culprits. In women, hormonal changes at the time of men-
struation may be a trigger. In some patients, the triggers are 
very clear. In other patients, the triggers are less well-defined, 
such as the role of peptide serotonin, which is neurologically 
active and does not usually circulate in blood heading from 
the heart to the brain. By closing the PFO, it is thought that 
these vasoactive substances are prevented from reaching the 
blood vessels in the head, removing a major migraine trig-
ger. If true migraine or migraine-like symptoms are due to 
transient ischemic attacks (TIA) or paradoxic embolism is 
another query to be solved.
The link between migraine headaches and PFO was found 
only recently and by chance. The observation was made in 
patients with cryptogenic stroke and a PFO who also had mi-
graine headaches. After these patients had their PFO closed to 
prevent recurrent strokes, many of them reported a dramatic 
reduction in migraine frequency. This link was looked at sys-
tematically by a number of investigators [5]. Schwerzmann and 
his colleagues at the University Inselspital Hospital in Bern, 
Switzerland, compared 93 patients suffering from migraine 
headaches with aura with 93 healthy controls [17]. They found 
that 47% of the migraine sufferers had a PFO. In contrast, 
only 17% of the controls had a PFO. These researchers found 
that patients afflicted by migraine were much more likely to 
have mid-sized or large PFOs, while those of the controls 
were generally small. This team of investigators found that 
migrainous headaches in patients who have had their PFOs 
closed were significantly improved or even eliminated.
Two groups of researchers from Belgium and Switzerland 
studied whether percutaneous closure would lead to fewer 
migraines. The Belgian group gave a questionnaire about 
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migraines to people after they had the PFO closed [18]. The 
Swiss group gave a questionnaire assessing the headache 
frequency and characteristics for the year before and after 
the PFO closure [19]. There was no appreciable effect on the 
non- migraine headache patients. In both studies, the PFO 
closure was done for cryptogenic stroke. The frequency of mi-
graine was decreased in both studies after PFO closure. Only 
the Swiss study evaluated both migraine and non-migraine 
headaches. These studies add to the growing body of evidence 
that there is an association between a PFO and migraine. 
First, the number of people who had migraine with aura in 
both studies was higher than in the general population. Sec-
ond, PFO closure was associated with reduction of migraine 
symptoms in patients having migraine both with and without 
aura. Third, in the second study, non migraine headaches were 
not affected by PFO closure. These studies are important in 
that they provide a clue to a potentially correctable trigger 
of migraine. However, they do not support PFO closure as a 
treatment for migraine because of two major limitations. The 
studies were retrospective, they asked patients for informa-
tion about their headaches that occurred in the past; and they 
studied only stroke patients. To get better results, a study is 
needed that evaluates otherwise healthy migraine patients and 
collects information in real time, prospectively, and treatment 
is allocated in a randomized manner.
The prevalence of migraine was very high in patients with 
stroke or decompression sickness who had PFOs. A series of 
five studies with those patients evaluated or treated for PFO 
/ right- to- left shunts has demonstrated an overall prevalence 
of migraine of 22-57%, migraine with aura of 18-43% and 
migraine without aura of 14-21% [18-22]. Studies have also 
shown that the prevalence of migraine is higher with larger 
shunts [23].
Another study determined the effects of transcatheter 
PFO closure on migraine frequency in patients with para-
doxical cerebral embolism [5]. A cohort of 162 patients with 
paradoxical cerebral embolism underwent transcatheter 
PFO closure for prevention of recurrent cryptogenic stroke 
or transient ischemic attacks. A one-year retrospective analy-
sis of migraine symptoms before and after PFO closure was 
performed. Migraine symptoms were completely relieved in 
56%, significantly reduced in 14% of patients and 30% re-
ported minimal or no relief of migraine. The conclusion was 
that in patients with paradoxical cerebral embolism, migraine 
headaches are more frequent than in the general population 
and transcatheter closure of the PFO results in complete 
resolution or marked reduction in the frequency of migraine 
headache. Although many migraine sufferers are eager for 
any procedure that could offer them potential relief from 
the debilitating attack, controlled clinical trials are needed 
before recommending PFO closure procedures as a possible 
migraine treatment. There are migraine sufferers who do not 
have interatrial shunts, and people with PFOs and ASDs who 
do not suffer from migraine; so the link seen in this study, even 
if confirmed, does not explain all migraines.
Overall there are at least seven studies that show that per-
cutaneous PFO closure cures migraine or offers significant 
improvement [25]. However, despite the promising findings 
and advances, most researchers do not yet consider that PFO 
closure is ready for prime-time use in treating migraines, as 
these studies thus far have not been randomized and prop-
erly designed to rule out alternative explanations for patients’ 
improvement. Researchers also do not know whether these 
findings apply to patients with migraines but without strokes 
or other problems that have been previously associated with 
a PFO. It has been suggested that the relief of headaches 
might be a response to clopidogrel which these patients 
usually receive and this would be in keeping with the role of 
platelets as a potentially major etiologic factor. Further stud-
ies are clearly needed to investigate the role of clopidogrel 
or of the combination of clopidogrel and aspirin therapy in 
these settings [26]. Nevertheless, some data indicate that the 
relief of headaches persists even after discontinuation of the 
antithrombotic therapy usually slated at 5-6 months after the 
device implant procedure.
To date no isolated data have been published about the 
relationship between migraine and the presence of an atrial 
septal defect. Although an ASD is mainly characterized by a 
left to right shunt and volume overload of the right heart, a 
small right to left shunt may occur during Valsalva or exercise. 
Theoretically, this right to left shunt could also permit the 
lung filter to be bypassed. Indeed, there is a high prevalence 
of migraine in patients with an unclosed secundum type ASD 
(up to 30%) [27]. This seems to be higher than in the general 
population, but lower than in patients with PFO [2].
O N G O I N G  R A N D O M I Z E D  S T U D I E S
All PFO closure studies so far have been non-randomized, 
fairly small and observational. To establish a true benefit from 
PFO closure, large randomized controlled trials are required. 
Such trials are currently ongoing. The preliminary results of 
the first such study, the ‘MIST’ (Migraine Intervention with 
STARFlex Technology) trial, which was conducted in the 
UK, were just presented during the 2006 American College 
of Cardiology annual meeting in Atlanta [23,24]. These results 
confirmed previous studies showing that medium-to-large 
cardiac shunts, mostly PFOs are common in patients having 
migraine with aura. The prevalence of small shunts was little 
different from that seen in the general population, but the 
prevalence of medium-to-large PFOs was about 6-fold greater 
than expected. The MIST trial randomized 147 patients to 
PFO closure with the STARFlex device (n=74) or to a sham 
procedure (control group; n=73). Patients were followed for 
6 months evaluating migraine frequency and severity; patients 
76
HOSPITAL CHRONICLES, SUPPLEMENT 2006 PFO AND MIGRAINE
77
were treated with aspirin and clopidogrel for the first 3 months. 
The study showed that there was no difference between the 
two groups in the primary endpoint of complete cessation 
of migraines (only 3 patients in each group had elimination 
of migraine). However, headache reduction by at least 50% 
occurred more frequently in the PFO closure group (42% vs 
23%, p=0.038).
More randomized, double-blind, placebo-controlled stu-
dies currently recruiting patients with migraine and a PFO 
include the MIST II trial conducted in the US (550 patients), 
the “ESCAPE” (‘Effect of Septal Closure of Atrial PFO on 
Events of Migraine with Premere’) trial, also conducted in 
the US, the FORMAT (“Patent Foramen Ovale Closure to 
Reduce Migraine Attacks”) trial (Holland & Belgium), and 
the PREMIUM (“Prospective Randomized Investigation to 
Evaluate Incidence of Headache Reduction In Subjects with 
Migraine & PFO Using the Amplatzer PFO Occluder Com-
pared to Medical Management”) trial (USA) [27].
C O N C L U S I O N
Despite the promising findings and advances, most re-
searchers do not think that PFO closure is ready for prime 
time use in treating migraines. They harbor lingering doubts 
because the studies thus far were not designed to rule out 
alternative explanations for the volunteers’ improvements. 
Researchers also do not know whether the findings apply to 
people with migraines but without strokes or other problems 
that have been previously associated with a PFO. As indi-
cated above, several randomized clinical trials are currently 
ongoing, and it is expected that within two years, we could 
have conclusive evidence whether PFO closure works against 
migraines. If these studies confirm the initial findings, mil-
lions of people could consider closure of PFOs as a treatment 
option for migraines.
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